[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complex-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complex-coronary-artery-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100608530","procedural-complications-and-long-term-mortality-in-complex-coronary-interventions-100608530",false,"NCT07202754","Procedural Complications and Long-Term Mortality in Complex Coronary Interventions","The Impact of Procedural Complications on Long-Term Mortality in Complex Coronary Interventions: The Multicenter COMPLEX-ANATOLIA Study","Inclusion Criteria:\n\n* Patients with complex coronary disease\n* Aged 18-85 years\n\nExclusion Criteria:\n\n* Patients diagnosed with cardiogenic shock\n* Coronary lesions with non-complex features\n* Percutaneous coronary intervention with a bare metal stent\n* Patient life expectancy \\\u003C1 year\n* Known relevant allergies\n* Absence of all medical records\n* Patients with early discontinuation of dual antiplatelet therapy","ALL","18 Years","85 Years",{"count":20,"type":21},20000,"ESTIMATED","OBSERVATIONAL","The relative risks for different non-fatal intraprocedural complications during complex percutaneous coronary intervention (PCI) on subsequent mortality have not been described. This study aimed to assess the association between non-fatal intraprocedural complications and late mortality after complex coronary PCI.",[25],"Complex Coronary Artery Disease",[27],"Complications, death, major adverse cardiac events, target vessel revascularization","NOT_YET_RECRUITING","2025-10-01",{"date":31,"type":32},"2025-10-02","ACTUAL",{"date":34,"type":21},"2025-11-01",{"date":36,"type":21},"2026-03-01",{"name":38,"class":39},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","OTHER_GOV",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100564178","ivus-chip-upp-registry-100564178","NCT06625801","IVUS CHIP UPP Registry","Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures in Underrepresented Patient Populations Registry","Inclusion Criteria:\n\n1. The patient must be ≥18 years of age and self-identify within a US census-defined minority\n2. Patients with an indication for PCI of at least one lesion satisfying any of the following criteria:\n\n   1. Angiographic heavy calcification\n   2. Ostial lesions\n   3. True bifurcation lesions involving side-branches \\>2.5mm\n   4. Left main lesions\n   5. Chronic total occlusion\n   6. In-stent restenosis\n   7. Long-lesions (estimated stent length \\> 28mm) OR Patient with an indication for PCI for any lesion and in need for elective mechanical circulatory support assisted PCI\n3. Presenting with silent ischemia, stable angina, unstable angina or non-ST-elevation acute coronary syndrome (NSTE-ACS)\n4. All lesions must be suitable for treatment with FDA-approved contemporary generation drug eluting stents or drug-coated balloons\n5. The patient is willing and able to cooperate with registry procedures and follow-up until registry completion\n6. Subject is able to confirm understanding of risks, benefits and treatment alternatives and he\u002Fshe (or an authorized legal representative) provides informed consent prior to any protocol-related procedure, as approved by the appropriate IRB\n\nExclusion Criteria:\n\n1. ST-elevation myocardial infarction or cardiogenic shock within prior 7 days\n2. Known untreated severe valvular heart disease\n3. Contraindication on the use of IVUS (i.e. extreme vessel tortuosity)\n4. Requiring PCI in a diseased aorto-coronary bypass\n5. Known contraindication or hypersensitivity to anticoagulants\n6. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors\n7. Non-cardiac co-morbidities with a life expectancy less than 1 year\n8. A patients that is currently participating in a clinical trial that has not yet reached its primary endpoint cannot be included in this registry. A patient may only be enrolled in this registry once.",{"count":48,"type":21},1010,"24 Months","The IVUS CHIP UPP Registry is a prospective, observational, multicenter, single-arm registry. A total of 1010 patients with complex coronary lesions will be enrolled in up to 2 years, with at least 500 men and women. All patients will be treated with IVUS-guided PCI.",[52,53,25],"Coronary Artery Disease","Coronary Artery Disease Risk High",[55,56,57,58],"PCI","intravascular ultrasound","CHIP","ivus-guidance","2025-08-25",{"date":61,"type":32},"2025-09-02",{"date":63,"type":21},"2025-09",{"date":65,"type":21},"2029-03",{"name":67,"class":68},"ECRI bv","INDUSTRY"]